Intralesional Ethanolamine Oleate Injection for Management of Venous Malformations: Case series

Objective: Venous Malformations can result in severe functional and aesthetic disorders, modern trendstoward sclerotherapy are backed by the fear of the potential risk of injuring vital structures associatedwith the traditional surgical approach. This study is presenting our center experience with intralesionalEthanolamine Oleate (EAO) in the management of VMs, over a period of 12 months.Method: This study is a retrospective review of a cohort of 13 patients who were presented with VMs. Allthe cases were treated with intralesional injection of EAO 5%. A standardized set of data for each patient wasrecorded including demographic and clinical data. A dose of 1 cc diluted in 4 cc distilled water, 6 sessions,at 7 days interval. Before injection aspiration was done, all the cases were injected by the same operator.Results: Thirteen patients were managed with serial injections of intralesional EAO 5% with a mean ageof 3.5 years (range from 8 months to 12 years). The mean follow up was 7 months (range from 3 to 12months). The average number of sessions was 5.2 ± 0.79. Recorded clinical response was;complete responsein 5/13 (38.6%), marked improvement was detected in 4/13 (30.7%). Two cases (15.3%) showed moderateimprovement and 1 case (7.6%) recorded a slight response. Only one case (7.6%) showed no response totreatment. No systemic adverse effects were reported.Conclusion: Intralesional EAO injection is an effective and safe modality for treating VMs in the pediatricage group.